Serum cytokine profiles in patients with prostate carcinoma

Tazaki, Eri; Shimizu, Nobuaki; Tanaka, Ryota; Yoshizumi, Masakazu; Kamma, Hiroshi; Imoto, Shigeru; Goya, Tomoyuki; Kozawa, Kunihisa; Nishina, Atsuyoshi; Kimura, Hirokazu

doi:10.3892/etm.2011.286

Cited by 40 publications

(38 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From this profile, when compared to that of the control group, it appears that serum levels of all cytokines were significantly higher in the cachexia group, and six cytokines (IL-1 β , IL-2, IL-8, IL-12, TNF- α , and IFN- γ ) were significantly higher in the group with advanced Pca without cachexia. However, in the group with organ-confined Pca, only IL-1 β and IL-12 levels were significantly higher compared to the control group [51]. Therefore, the cytokinome profile can be useful to identify new markers of disease progression in presence or absence of other comorbidities.…”

Section: “Cytokinome” and Prostate Cancermentioning

confidence: 99%

Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays

Capone

Guerriero

Sorice

et al. 2016

Mediators of Inflammation

View full text Add to dashboard Cite

In recent years, many researchers are focusing their attention on the link between inflammation and cancer. The inflammation is involved in the tumor development and suppression, by stimulating the immune response. In particular, the transition from chronic inflammation to cancer produces angiogenic and growth factors able to repair the tissue and to promote cancer cell survival, implantation, and growth. In this contest, the cytokines contribute to the development of these processes becoming active before and during the inflammatory process and playing an important function at the various disease levels. Thus, these proteins can represent specific markers of tumor development and progression. Therefore the “cytokinome” term is used to indicate the evaluation of cytokine pattern by using an “omics” approach. Newly, specific protein chips of considerable and improved sensitivity are being developed to determine simultaneously several and different cytokines. This can be achieved by a multiplex technology that, through the use of small amounts of serum or other fluids, is used to determine the presence and the levels of underrepresented cytokines. Since this method is an accurate, sensitive, and reproducible cytokine assay, it is already used in many different studies. Thus, this review focuses on the more latest aspects related to cytokinome profile evaluation in different cancers.

show abstract

Section: “Cytokinome” and Prostate Cancermentioning

confidence: 99%

Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays

Capone

Guerriero

Sorice

et al. 2016

Mediators of Inflammation

View full text Add to dashboard Cite

show abstract

“…Epithelial prostate cells (both androgen-dependent and independent) influence the growth and differentiation of both normal cells and cancer cells. It has been shown that the epithelial prostate cells produce pro-inflammatory cytokines 2 , which suggests that cytokines are associated with the pathophysiology of the prostate cancer 3 . In healthy people, immune system components specifically recognize and eliminate tumor cells.…”

Section: Introductionmentioning

confidence: 99%

“…Cytokines produced from tumourous cells and infiltrating immune cells are important factors which enable the survival of tumourous cells and their growth in spite of the existence of tumor specific response. So far, several studies focused on cytokines determined in the blood samples, prostate exprimate and urine of the patients with prostate cancer (CP) 3,7,8,9,10,11 Control group consisted of 20 men with benign prostatic hyperplasia and 15 healthy men (regular physical examination) that had never suffered from active/chronic genito urinary diseaase or any malignant diseases. Tumourous tissue samples for further pathohistological analysis were obtained during the surgical procedure of the CP patients who had undergone the surgery.…”

Section: Introductionmentioning

confidence: 99%

High level of interleukin-10 in serum after therapy is characteristic of prostate carcinoma patients with high Gleason score, high tumor volume and present peritumoral infiltration

Jovanovic

Bančević

Jovanovic³

et al. 2021

VOJNOSANIT PREGL

View full text Add to dashboard Cite

Background/Aim. Recent data implicate at significance of certain cytokines in the appearance and development of CP, as well as their association with pathohistological and/or clinical characteristics of prostate cancer. The aim of our study was to examine the relationship between the IL-10 concentration with pathohistological and clinical disease characteristics of CP patients. Methods. IL-10 concentration was determined in serum, urine and pms samples of 88 CP patients (initially and after therapy), 20 BPH patients and 15 healthy controls. Results. Comparing to BPH and control groups, CP patients had the highest average sera IL-10 concentration. Interestingly, BPH patients demonstrated the highest concentration in urine and pms samples. Also, patients with G3 gradus and with the highest Gleason score (4+4) demonstrated the highest IL-10 sera level. CP patients without any patohistological sign of tumor invasion had significantly increased serum IL-10, either before or after therapy, comparing to patient group with evident invasion of tumor cells. Therapy induced different IL-10 profile in serum and urine samples. After therapy there was clear significant IL-10 increase in sera of patients of unfavorable Gleason score (4+4), with present infiltration of tumor cells in peritumor tissue (lymphatic, vascular and combined) and in patients with high tumor volumen. Conclusion. CP patients without any pathohistological signs of tumor invasion before therapy have significantly increased serum IL-10 concentration comparing to those with signs of tumor invasion. There is a clear dissociation of IL-10 value between a serum sample and local, urine and pms samples from particular patient. After therapy, high IL-10 sera concentration is present only in patients with high Gleason score, present infiltration of peritumor tissue and high tumor volume.

show abstract

“…Interleukin-1 (IL-1) is an inflammatory cytokine present in tumors that promotes tumor angiogenesis and metastasis [7]. IL-1 is elevated in BCa and PCa tumors [8][9][10][11][12][13] and correlates with low or lost ERα or AR accumulation [10,[14][15][16][17]. We discovered that IL-1 downregulates ERα and AR levels in HR + BCa and PCa cell lines concomitant with the upregulation of pro-survival proteins that are basally high in HR − cell lines [18,19].…”

Section: Introductionmentioning

confidence: 99%

IL-1-conferred gene expression pattern in ERα+ BCa and AR+ PCa cells is intrinsic to ERα− BCa and AR− PCa cells and promotes cell survival

et al. 2020

View full text Add to dashboard Cite

Background: Breast (BCa) and prostate (PCa) cancers are hormone receptor (HR)-driven cancers. Thus, BCa and PCa patients are given therapies that reduce hormone levels or directly block HR activity; but most patients eventually develop treatment resistance. We have previously reported that interleukin-1 (IL-1) inflammatory cytokine downregulates ERα and AR mRNA in HR-positive (HR +) BCa and PCa cell lines, yet the cells can remain viable. Additionally, we identified pro-survival proteins and processes upregulated by IL-1 in HR + BCa and PCa cells, that are basally high in HR − BCa and PCa cells. Therefore, we hypothesize that IL-1 confers a conserved gene expression pattern in HR + BCa and PCa cells that mimics conserved basal gene expression patterns in HR − BCa and PCa cells to promote HR-independent survival and tumorigenicity. Methods: We performed RNA sequencing (RNA-seq) for HR + BCa and PCa cell lines exposed to IL-1 and for untreated HR − BCa and PCa cell lines. We confirmed expression patterns of select genes by RT-qPCR and used siRNA and/or drug inhibition to silence select genes in the BCa and PCa cell lines. Finally, we performed Ingenuity Pathway Analysis (IPA) and used the gene ontology web-based tool, GOrilla, to identify signaling pathways encoded by our RNA-seq data set. Results: We identified 350 genes in common between BCa and PCa cells that are induced or repressed by IL-1 in HR + cells that are, respectively, basally high or low in HR − cells. Among these genes, we identified Sequestome-1 (SQSTM1/p62) and SRY (Sex-Determining Region Y)-Box 9 (SOX9) to be essential for survival of HR − BCa and PCa cell lines. Analysis of publicly available data indicates that p62 and SOX9 expression are elevated in HR-independent BCa and PCa sublines generated in vitro, suggesting that p62 and SOX9 have a role in acquired hormone receptor independence and treatment resistance. We also assessed HR − cell line viability in response to the p62-targeting drug, verteporfin, and found that verteporfin is cytotoxic for HR − cell lines. Conclusions: Our 350 gene set can be used to identify novel therapeutic targets and/or biomarkers conserved among acquired (e.g. due to inflammation) or intrinsic HR-independent BCa and PCa.

show abstract

Serum cytokine profiles in patients with prostate carcinoma

Cited by 40 publications

References 27 publications

Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays

Serum Cytokinome Profile Evaluation: A Tool to Define New Diagnostic and Prognostic Markers of Cancer Using Multiplexed Bead-Based Immunoassays

High level of interleukin-10 in serum after therapy is characteristic of prostate carcinoma patients with high Gleason score, high tumor volume and present peritumoral infiltration

IL-1-conferred gene expression pattern in ERα+ BCa and AR+ PCa cells is intrinsic to ERα− BCa and AR− PCa cells and promotes cell survival

Contact Info

Product

Resources

About